Cargando…

Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

BACKGROUND: From January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant. The UK COVID-19 vaccination programme started on 8th December 2020. Prior to the Delta v...

Descripción completa

Detalles Bibliográficos
Autores principales: Pattni, Karan, Hungerford, Daniel, Adams, Sarah, Buchan, Iain, Cheyne, Christopher P., García-Fiñana, Marta, Hall, Ian, Hughes, David M., Overton, Christopher E., Zhang, Xingna, Sharkey, Kieran J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934524/
https://www.ncbi.nlm.nih.gov/pubmed/35307024
http://dx.doi.org/10.1186/s12879-022-07239-z
_version_ 1784671866377469952
author Pattni, Karan
Hungerford, Daniel
Adams, Sarah
Buchan, Iain
Cheyne, Christopher P.
García-Fiñana, Marta
Hall, Ian
Hughes, David M.
Overton, Christopher E.
Zhang, Xingna
Sharkey, Kieran J.
author_facet Pattni, Karan
Hungerford, Daniel
Adams, Sarah
Buchan, Iain
Cheyne, Christopher P.
García-Fiñana, Marta
Hall, Ian
Hughes, David M.
Overton, Christopher E.
Zhang, Xingna
Sharkey, Kieran J.
author_sort Pattni, Karan
collection PubMed
description BACKGROUND: From January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant. The UK COVID-19 vaccination programme started on 8th December 2020. Prior to the Delta variant, most vaccine effectiveness studies focused on the alpha variant. We therefore aimed to estimate the effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in preventing symptomatic and asymptomatic infection with respect to the Delta variant in a UK setting. METHODS: We used anonymised public health record data linked to infection data (PCR) using the Combined Intelligence for Population Health Action resource. We then constructed an SIR epidemic model to explain SARS-CoV-2 infection data across the Cheshire and Merseyside region of the UK. Vaccines were assumed to be effective after 21 days for 1 dose and 14 days for 2 doses. RESULTS: We determined that the effectiveness of the Oxford-AstraZeneca vaccine in reducing susceptibility to infection is 39% (95% credible interval [34, 43]) and 64% (95% credible interval [61, 67]) for a single dose and a double dose respectively. For the Pfizer-BioNTech vaccine, the effectiveness is 20% (95% credible interval [10, 28]) and 84% (95% credible interval [82, 86]) for a single-dose and a double dose respectively. CONCLUSION: Vaccine effectiveness for reducing susceptibility to SARS-CoV-2 infection shows noticeable improvement after receiving two doses of either vaccine. Findings also suggest that a full course of the Pfizer-BioNTech provides the optimal protection against infection with the Delta variant. This reinforces the need to complete the full course programme to maximise individual protection and reduce transmission. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07239-z.
format Online
Article
Text
id pubmed-8934524
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89345242022-03-21 Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2 Pattni, Karan Hungerford, Daniel Adams, Sarah Buchan, Iain Cheyne, Christopher P. García-Fiñana, Marta Hall, Ian Hughes, David M. Overton, Christopher E. Zhang, Xingna Sharkey, Kieran J. BMC Infect Dis Research Article BACKGROUND: From January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant. The UK COVID-19 vaccination programme started on 8th December 2020. Prior to the Delta variant, most vaccine effectiveness studies focused on the alpha variant. We therefore aimed to estimate the effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in preventing symptomatic and asymptomatic infection with respect to the Delta variant in a UK setting. METHODS: We used anonymised public health record data linked to infection data (PCR) using the Combined Intelligence for Population Health Action resource. We then constructed an SIR epidemic model to explain SARS-CoV-2 infection data across the Cheshire and Merseyside region of the UK. Vaccines were assumed to be effective after 21 days for 1 dose and 14 days for 2 doses. RESULTS: We determined that the effectiveness of the Oxford-AstraZeneca vaccine in reducing susceptibility to infection is 39% (95% credible interval [34, 43]) and 64% (95% credible interval [61, 67]) for a single dose and a double dose respectively. For the Pfizer-BioNTech vaccine, the effectiveness is 20% (95% credible interval [10, 28]) and 84% (95% credible interval [82, 86]) for a single-dose and a double dose respectively. CONCLUSION: Vaccine effectiveness for reducing susceptibility to SARS-CoV-2 infection shows noticeable improvement after receiving two doses of either vaccine. Findings also suggest that a full course of the Pfizer-BioNTech provides the optimal protection against infection with the Delta variant. This reinforces the need to complete the full course programme to maximise individual protection and reduce transmission. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07239-z. BioMed Central 2022-03-20 /pmc/articles/PMC8934524/ /pubmed/35307024 http://dx.doi.org/10.1186/s12879-022-07239-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Pattni, Karan
Hungerford, Daniel
Adams, Sarah
Buchan, Iain
Cheyne, Christopher P.
García-Fiñana, Marta
Hall, Ian
Hughes, David M.
Overton, Christopher E.
Zhang, Xingna
Sharkey, Kieran J.
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
title Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
title_full Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
title_fullStr Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
title_full_unstemmed Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
title_short Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
title_sort effectiveness of the bnt162b2 (pfizer-biontech) and the chadox1 ncov-19 (oxford-astrazeneca) vaccines for reducing susceptibility to infection with the delta variant (b.1.617.2) of sars-cov-2
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934524/
https://www.ncbi.nlm.nih.gov/pubmed/35307024
http://dx.doi.org/10.1186/s12879-022-07239-z
work_keys_str_mv AT pattnikaran effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2
AT hungerforddaniel effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2
AT adamssarah effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2
AT buchaniain effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2
AT cheynechristopherp effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2
AT garciafinanamarta effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2
AT hallian effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2
AT hughesdavidm effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2
AT overtonchristophere effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2
AT zhangxingna effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2
AT sharkeykieranj effectivenessofthebnt162b2pfizerbiontechandthechadox1ncov19oxfordastrazenecavaccinesforreducingsusceptibilitytoinfectionwiththedeltavariantb16172ofsarscov2